CN101926800B - 含有氨力农的药用组合物及其制备方法和应用 - Google Patents
含有氨力农的药用组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN101926800B CN101926800B CN2010102346595A CN201010234659A CN101926800B CN 101926800 B CN101926800 B CN 101926800B CN 2010102346595 A CN2010102346595 A CN 2010102346595A CN 201010234659 A CN201010234659 A CN 201010234659A CN 101926800 B CN101926800 B CN 101926800B
- Authority
- CN
- China
- Prior art keywords
- amrinone
- temperature
- freeze
- add
- hour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 229960002105 amrinone Drugs 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 29
- 229930195725 Mannitol Natural products 0.000 claims abstract description 29
- 239000000594 mannitol Substances 0.000 claims abstract description 29
- 235000010355 mannitol Nutrition 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 21
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical group [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 21
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 21
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 238000004108 freeze drying Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 239000000047 product Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 21
- 238000002347 injection Methods 0.000 claims description 21
- 210000004204 blood vessel Anatomy 0.000 claims description 20
- 239000003610 charcoal Substances 0.000 claims description 20
- 230000001954 sterilising effect Effects 0.000 claims description 20
- 239000004310 lactic acid Substances 0.000 claims description 19
- 235000014655 lactic acid Nutrition 0.000 claims description 19
- 230000033228 biological regulation Effects 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- 238000012546 transfer Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 10
- 229940105082 medicinal charcoal Drugs 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 239000012982 microporous membrane Substances 0.000 claims description 10
- 230000003130 cardiopathic effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 abstract description 17
- 230000003078 antioxidant effect Effects 0.000 abstract description 17
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract description 4
- 239000000600 sorbitol Substances 0.000 abstract description 4
- 230000002792 vascular Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000008215 water for injection Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 235000006708 antioxidants Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000013019 agitation Methods 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 5
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 5
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006324 decarbonylation Effects 0.000 description 1
- 238000006606 decarbonylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102346595A CN101926800B (zh) | 2010-07-23 | 2010-07-23 | 含有氨力农的药用组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102346595A CN101926800B (zh) | 2010-07-23 | 2010-07-23 | 含有氨力农的药用组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101926800A CN101926800A (zh) | 2010-12-29 |
CN101926800B true CN101926800B (zh) | 2011-12-07 |
Family
ID=43366405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102346595A Active CN101926800B (zh) | 2010-07-23 | 2010-07-23 | 含有氨力农的药用组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101926800B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106117166A (zh) * | 2016-06-23 | 2016-11-16 | 崔坤峰 | 氨力农的药物组合物及其在高血压治疗中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1064232C (zh) * | 1996-10-04 | 2001-04-11 | 齐鲁制药厂 | 一种治疗心脏病药物的非冻干型粉针制剂及制备方法 |
CN1879622A (zh) * | 2005-06-13 | 2006-12-20 | 信谊药厂 | 注射用米力农冻干粉及其制备方法 |
-
2010
- 2010-07-23 CN CN2010102346595A patent/CN101926800B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101926800A (zh) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103508961B (zh) | 抗肿瘤药物 | |
CN105434373A (zh) | 一种注射用奥拉西坦冻干制剂及其制备方法 | |
CN101417995B (zh) | 苯氧基嘧啶衍生物及其制备方法和用途 | |
CN102302461B (zh) | 一种注射用丹曲林钠冻干粉针剂及其制备方法 | |
CN103864683B (zh) | 一种环丙沙星和水杨酸的药物共晶体及其制备工艺 | |
CN104918615A (zh) | 治疗肝病的方法 | |
CN101926800B (zh) | 含有氨力农的药用组合物及其制备方法和应用 | |
CN102276533B (zh) | 一种新的奥扎格雷钠化合物及其药物组合物 | |
CN102258488A (zh) | 一种注射用克林霉素磷酸酯组合物及其制备方法 | |
CN101380329B (zh) | 一种精氨酸阿司匹林及其粉针剂的制备方法 | |
CN103980279B (zh) | 一种甲氨蝶呤化合物及注射用甲氨蝶呤 | |
CN104922080A (zh) | 治疗消化系统疾病的药物艾普拉唑钠冻干粉针剂组合物 | |
CN102949353B (zh) | 一种注射用奥沙利铂冻干药物组合物的制备 | |
CN103159817A (zh) | 一种琥珀酸甲泼尼龙的制备方法 | |
CN103520192B (zh) | 一种注射用转化糖冻干粉针制剂制备方法 | |
CN108289897B (zh) | 一种瑞马唑仑的药物组合物 | |
CN102836132A (zh) | 一种甲磺酸萘莫司他冻干粉针剂 | |
CN104825438A (zh) | 治疗消化系统疾病的药物盐酸雷尼替丁冻干粉针剂组合物 | |
FI59336B (fi) | Foerfarande foer framstaellning av en oevermaettad isosorbiddinitratloesning | |
CN101658498B (zh) | 三磷酸胞苷二钠与精氨酸的冻干制品及其制备方法 | |
CN105193746A (zh) | 一种降压药乌拉地尔组合物冻干粉针剂 | |
CN103006584B (zh) | 一种注射用培美曲塞二钠的制备方法 | |
CN103494778B (zh) | 一种埃索美拉唑钠冻干制剂及其制备方法 | |
CN104224796A (zh) | 齐墩果烷型三萜类酯衍生物抗神经退行性药物用途 | |
CN100450476C (zh) | 注射用电解质补充药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN HUALON PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHEN YIZHI Effective date: 20110801 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20110801 Address after: 571127, Hainan Guilin Economic Development Zone, Haikou City, Hainan Province, Limited by Share Ltd pharmaceutical company Applicant after: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Address before: 571127 Haikou Guilin Economic Development Zone, Hainan, China Applicant before: Chen Yizhi |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing amrinone and preparation method and application thereof Effective date of registration: 20150728 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2015460000003 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170328 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2015460000003 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing amrinone and preparation method and application thereof Effective date of registration: 20170427 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000005 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170524 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000005 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing amrinone and preparation method and application thereof Effective date of registration: 20170526 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000008 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180720 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Sanya branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2017460000008 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing amrinone and preparation method and application thereof Effective date of registration: 20180920 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2018460000008 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191031 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: 2018460000008 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing amrinone and its preparation method and Application Effective date of registration: 20200929 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980006541 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220419 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980006541 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition containing amrinone and its preparation method and Application Effective date of registration: 20220526 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006463 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Yao Zhenhong Document name: Notice of Approval for Restoration of Rights Request |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230726 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006463 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition containing amrinone and its preparation method and application Effective date of registration: 20230804 Granted publication date: 20111207 Pledgee: China Minsheng Banking Corp Haikou branch Pledgor: HAINAN HUALON PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980051088 |